A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of a Single 20 mg Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine With or Without Aura

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of a Single 20 mg Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine With or Without Aura

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2016

At a glance

  • Drugs Sumatriptan (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Acronyms TARGET
  • Sponsors OptiNose
  • Most Recent Events

    • 09 Jun 2016 According to Avanir media release, results will be presented at the 58th American Headache Society Annual Scientific Meeting.
    • 15 Apr 2016 According to an Avanir Pharmaceuticals media release, efficacy analysis from this trial will be presented at the 68th American Academy of Neurology (AAN) Annual Meeting.
    • 28 Jan 2016 According to an OptiNose media release, the US FDA has approved sumatriptan nasal powder (ONZETRA Xsail; AVP-825) for the acute treatment of migraine with or without aura in adults.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top